The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population

  • Dusty Lisi
  • Ebony Andrews
  • Chelsea Parry
  • Catrina Hill
  • David Ombengi
  • Hua LingEmail author
Review Article


Ranolazine is an anti-anginal medication that reduces the sodium-dependent calcium overload via the inhibition of the late sodium current. After its approval for the treatment of chronic angina in 2006 in the USA, ranolazine has been reported to have several pleiotropic effects on various cardiac conditions, such as atrial fibrillation, ventricular arrhythmias, diastolic and microvascular dysfunction, and pulmonary arterial hypertension. Recently, several studies reported some promising results on the potential benefits of ranolazine on glycemic control. Though the mechanism of the antihyperglycemic effect is still unknown, ranolazine may exert the effect through β cell preservation, inhibition of glucose secretion, and enhancement of insulin secretion in a glucose-dependent manner. Given the increased risk of cardiovascular disease in patients with diabetes, it will be useful if one medication can simultaneously improve chronic angina and diabetes. Therefore, ranolazine could be a favored choice among other anti-anginal agents for patients with comorbidity of chronic angina and diabetes mellitus. In this review, we summarize the available data from clinical studies and provide valuable insight into defining the target population for the antihyperglycemic effect of ranolazine.


Ranolazine Glycemic control Narrative review 



  1. 1.
    Nash DT, Nash SD. Ranolazine for chronic stable angina. Lancet. 2008;372(9646):1335–41.CrossRefGoogle Scholar
  2. 2.
    Banerjee K, et al. Role of ranolazine in cardiovascular disease and diabetes: exploring beyond angina. Int J Cardiol. 2017;227:556–64.CrossRefGoogle Scholar
  3. 3.
    Gilbert BW, et al. Antihyperglycemic and metabolic effects of ranolazine in patients with diabetes mellitus. Am J Cardiol. 2018;121(4):509–12.CrossRefGoogle Scholar
  4. 4.
    Greiner L, Hurren K, Brenner M. Ranolazine and its effects on hemoglobin A1C. Ann Pharmacother. 2016;50(5):410–5.CrossRefGoogle Scholar
  5. 5.
    Zeng X, et al. Efficacy and safety of ranolazine in diabetic patients: a systematic review and meta-analysis. Ann Pharmacother. 2017:1060028017747901.Google Scholar
  6. 6.
    Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006;113(20):2462–72.CrossRefGoogle Scholar
  7. 7.
    Dhalla AK, et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2009;297(5):H1923–9.CrossRefGoogle Scholar
  8. 8.
    Dhalla AK, et al. Blockade of Na+ channels in pancreatic alpha-cells has antidiabetic effects. Diabetes. 2014;63(10):3545–56.CrossRefGoogle Scholar
  9. 9.
    Ning Y, et al. Ranolazine increases beta-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J Pharmacol Exp Ther. 2011;337(1):50–8.CrossRefGoogle Scholar
  10. 10.
    Fu Z, et al. Ranolazine recruits muscle microvasculature and enhances insulin action in rats. J Physiol. 2013;591(20):5235–49.CrossRefGoogle Scholar
  11. 11.
    Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27(1):42–8.CrossRefGoogle Scholar
  12. 12.
    Morrow DA, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119(15):2032–9.CrossRefGoogle Scholar
  13. 13.
    Pettus J, et al. Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes Obes Metab. 2016;18(5):463–74.CrossRefGoogle Scholar
  14. 14.
    Fanaroff AC, et al. Ranolazine after incomplete percutaneous coronary revascularization in patients with versus without diabetes mellitus: RIVER-PCI Trial. J Am Coll Cardiol. 2017;69(18):2304–13.CrossRefGoogle Scholar
  15. 15.
    Zack J, et al. Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus. Clin Pharmacol Drug Dev. 2015;4(2):121–9.CrossRefGoogle Scholar
  16. 16.
    Eckel RH, et al. Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes. Diabetes Care. 2015;38(7):1189–96.CrossRefGoogle Scholar
  17. 17.
    Chisholm JW, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care. 2010;33(6):1163–8.CrossRefGoogle Scholar
  18. 18.
    Kipnes M, et al. A study to assess the metabolic effects of ranolazine when added to ongoing non-insulin medical therapy in subjects with type 2 diabetes mellitus (T2DM). Diabetes. 2011;60:A316.Google Scholar
  19. 19.
    Sandhiya S, et al. Comparison of ranolazine and trimetazidine on glycemic status in diabetic patients with coronary artery disease—a randomized controlled trial. J Clin Diagn Res. 2015;9(1):OC01–5.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Lopaschuk GD, et al. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2003;93(3):e33–7.CrossRefGoogle Scholar
  21. 21.
    Greiner L, Hurren K, Brenner M. The effects of ranolazine on hemoglobin A1c in a veteran population. Fed Pract. 2018;35(5):44–8.PubMedPubMedCentralGoogle Scholar
  22. 22.
    RANEXA® (ranolazine) extended-release tablets [package insert]. Foster City: Gilead Sciences, Inc; 2016.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Dusty Lisi
    • 1
  • Ebony Andrews
    • 2
  • Chelsea Parry
    • 1
  • Catrina Hill
    • 1
  • David Ombengi
    • 3
  • Hua Ling
    • 1
    Email author
  1. 1.Department of Pharmacy Practice, School of PharmacyGeorgia Campus—Philadelphia College of Osteopathic MedicineSuwaneeUSA
  2. 2.Department of Pharmacy Practice, School of PharmacyHampton UniversityHamptonUSA
  3. 3.Department of Clinical Sciences, School of Pharmacy and Department of Family and Community MedicineMedical College of WisconsinMilwaukeeUSA

Personalised recommendations